retatrutide clinical trials news Eli Lilly to offer access given earlier to just one patient What's at stake when clinical

Practice proper hygiene, injection techniques, and safety measures

The first cannabanoid-1 receptor antagonist to enter clinical trials was rimonabant, which showed excellent weight loss outcomes with an additional mean weight loss of 4.7 kg [102]

(The brand-name GLP-1s arent available as generics because the patents havent expiredNovo Nordisk has its US patent on semaglutide until 2032, and Eli Lilly on tirzepatide, until 2036.) But to be clear, compounders do still operate within a regulatory framework, albeit a less stringent one

The 2025 update also highlights CGM consideration for adults with type 2 diabetes on glucose-lowering agents beyond insulin when clinically appropriate